Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEZ235 with or without RAD001 for prevention of respiratory tract infections in high-risk elderly adults
ACTRN12617000468325Phase 2Completed
- Sponsor
- resTORbio
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dactolisib and everolimus in Airways Infection, sponsored by resTORbio. Primary endpoint: Incidence of respiratory tract infection at 16 weeks. Started May 2017; status: completed.
02
Drugs
dactolisibeverolimus
03
Conditions
Airways Infection
Beyond the preview
Go deeper on ACTRN12617000468325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000468325.